Tumeurs digestives rares: tumeur gastro-intestinale stromale (GIST): à propos d’un cas de localisation grêlique et revue de littérature

Bellamlih, Habib; Bouimetarhan, Lamiae; Amil, T.; En-Nouali, H.; Chouaib, Naoufal; Jidane, Said; Rafai, M.A.; Belkouch, Ahmed; Belyamani, Lahcen

doi:10.11604/pamj.2017.27.274.12708

Cited by 2 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gastrointestinal segments were defined as follows: stomach, the part close to pyloric sphincter; duodenum, at the site 1 cm below pyloric sphincter to ligament of Trietz; upper jejunum, at the site 5 cm below stomach (upper half of remaining small intestine); lower jejunum-ileum, at the site 5 cm above cecum (lower half of small intestine); colon, at the site 5 cm below ileum-cecum (cecum to rectum); and rectum, at the site 3 cm above anus [ 28 , 29 ].…”

Section: Methodsmentioning

confidence: 99%

Sites of gastrointestinal lesion induced by mycophenolate mofetil: a comparison with enteric-coated mycophenolate sodium in rats

Jia

Wang

et al. 2018

BMC Pharmacol Toxicol

View full text Add to dashboard Cite

BackgroundImmunosuppressant drugs for renal transplant mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS) cause gastrointestinal (GI) disorders. The specific site of GI tract targeted by MMF and EC-MPS remains unclear.MethodsIn this study, we investigated the effects of MMF and EC-MPS on stomach, duodenum, jejunum, ileum, colon and rectum using a rat model. Rats were randomized into five groups: control, MMF (100 mg/kg·d), mofetil (30 mg/kg·d), EC-MPS (72 mg/Kg·d), mofetil + EC-MPS. Each group was treated with drugs once a day for 7 days through intra-gastric gavage. Diarrhea grade of each rat were measured every day, as well as the body weight. Blood was collected by tail nick and Seven days later, the rats were sacrificed, GI tissues were collected for Histological research.ResultsThe results showed that diarrhea grade and weight loss were significantly higher in MMF group than other groups. The pathological score of MMF group was significantly higher than EC-MPS group and EC-MPS + mofetil group in jejunum and ileum tissues, but not other segments of GI tract. Absorption of EC-MPS is delayed, compared to that of MMF. MPAG concentration in duodenum, jejunum and ileum tissues of MMF group is higher than EC-MPS group. Mofetil may increase the magnitude of MPA absorption.ConclusionsOur data suggested that MMF might target jejunum and ileum and induce GI injury. EC-MPS causes less injury in GI tract than MMF, probably due to its kinetic property.

show abstract

Section: Methodsmentioning

confidence: 99%

Sites of gastrointestinal lesion induced by mycophenolate mofetil: a comparison with enteric-coated mycophenolate sodium in rats

Jia

Wang

et al. 2018

BMC Pharmacol Toxicol

View full text Add to dashboard Cite

show abstract

“…Tomografia computerizată cu contrast (CT) folosită în 12 cazuri (16,4%) fiind eficientă în detectarea cauzei și localizarea obstrucției biliare, deasemenea foarte util în diferențierea portalului hepatic sau a infiltrăriilor hepatice de tumori. CT este valoros în distingerea sindromului Mirizzi de un neoplasm, astfel oferă posibilitatea efectuării unui diagnostic diferențial [2].…”

Section: Materiale şI Metodeunclassified

“…Sindromul Mirizzi reprezintă o complicaţie tardivă şi rar întâlnită în evoluţia litiazei biliare, morfologic tradusă prin compresia hepato-coledocului cu formare de strictură la acest nivel sau fistulă colecisto-biliară, termenul de sindrom Mirizzi a fost adoptat pentru prima dată în lucrările efectuate de Pablo Luis Mirizzi în 1948 [2].…”

Section: Introducereunclassified

Mirizzi syndrome - diagnostic features and surgical treatment options

Cucu

Hotineanu

Ferdohleb

2023

BulMed

View full text Add to dashboard Cite

Mirizzi syndrome (MS) represents a rare clinical entity, being a challenge in biliary tract surgery. However, recent advances in technology have provided surgeons with new options for timely diagnosis and surgical treatment. Mirizzi syndrome currently has an incidence of 1%, representing 0.7-1.4% of all cholecystectomies performed. The study group included 73 patients treated in the clinic during the years 2000-2022, with attestation of the prevalence of type II MS. A combination of two or more diagnostic techniques increased the rate of preoperative diagnosis. The treatment was exclu- sively surgical adopted for the type of MS. Optimizing the methods of diagnosis and surgical treatment allows to increase the rate of objectification of the diagnosis and the choice of the surgical technique depending on the type of MS favoring the postoperative evolution.

show abstract

Tumeurs digestives rares: tumeur gastro-intestinale stromale (GIST): à propos d’un cas de localisation grêlique et revue de littérature

Cited by 2 publications

References 11 publications

Sites of gastrointestinal lesion induced by mycophenolate mofetil: a comparison with enteric-coated mycophenolate sodium in rats

Sites of gastrointestinal lesion induced by mycophenolate mofetil: a comparison with enteric-coated mycophenolate sodium in rats

Mirizzi syndrome - diagnostic features and surgical treatment options

Contact Info

Product

Resources

About